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Clinical Question 
What is the most appropriate therapy for a patient with a calf deep venous thrombosis (DVT)? 
Evidence-Based Answer 
Patients with a first episode of calf DVT with a transient risk factor should receive heparin 
therapy followed by oral anticoagulation for six to 12 weeks. [Strength of recommendation: A, 
based on systematic review of randomized controlled trials (RCTs)] If anticoagulation is 
contraindicated, physicians should monitor for proximal thrombus extension with duplex 
ultrasound twice weekly for two weeks. [Strength of recommendation: C, based on consensus 
guideline] The use of low-molecular-weight heparin (LMWH), outpatient therapy, compression 
stockings, elevation of the extremity, and early mobilization may be beneficial based on 
extrapolation from studies of proximal DVT. 
Evidence Summary 
A systematic review1 of the treatment of DVT conducted by the Agency for Healthcare Research 
and Quality (AHRQ) concluded that anticoagulation is beneficial for symptomatic calf DVT, 
based primarily on two studies of isolated calf thromboses. One RCT2 of 51 adults with calf 
DVT demonstrated that three months of warfarin treatment (International Normalized Ratio 
[INR] 2.5 to 4.2) significantly reduced the likelihood of recurrence, extension, and pulmonary 
embolism at three months (29 versus zero percent, number needed to treat [NNT]: 4) and one 
year (32 versus 4 percent, NNT: 4) compared to initial heparin followed by compression 
stockings alone. Another RCT3 compared six weeks of oral anticoagulation to 12 weeks of oral 
anticoagulation (INR 2 to 3) in 197 adults with a first episode of calf DVT. They found no 
statistically significant difference in recurrence rates (2 to 3 percent, respectively) or bleeding 
(13 to 22 percent, respectively) during 15 months of follow-up. All patients also received 
compression stockings and initial unfractionated heparin or LMWH therapy. 
Further recommendations for treating calf DVT come from studies of proximal DVT. Based on 
14 systematic reviews comparing LMWH to unfractionated heparin for initial treatment of any 
DVT (some with pulmonary emboli), the AHRQ review1 concluded that LMWH reduced the 
rate of thrombus extension, DVT recurrence, major bleeding, and death. However, reviews since 
1998 report smaller magnitudes of benefit than older reviews.1 A Cochrane systematic review4 
was updated in August, 2004, and came to similar conclusions. 
A 2001 Cochrane systematic review5 found limited evidence (three RCTs that excluded many 
patients and had other methodological flaws) that outpatient management of proximal DVT with 
unfractionated heparin or LMWH in selected patients did not increase complications. They noted 
that LMWH is likely to become common practice because of patient preference and cost 
savings.5 
Another Cochrane systematic review6 of proximal DVT found that graduated elastic 
compression stockings (20 to 40 mm Hg at the ankle) significantly reduced the likelihood of 
post-thrombotic syndrome two years later (NNT: 4; 95 percent confidence interval, 3 to 6).6 This 
syndrome of chronic leg discomfort, edema, and skin changes affects one third of patients with 
DVT within five years.6 
Recommendations from Others 
In the Seventh Conference on Antithrombotic and Thrombolytic Therapy, the American College 
of Chest Physicians (ACCP) recommends treating symptomatic isolated calf DVT with 
anticoagulation for three months (INR 2 to 3).7 They explicitly place higher value on 
"preventing recurrent thromboembolic events…[than] on bleeding and cost.”7  
The Institute for Clinical Systems Improvement (ICSI) notes: "Increasing evidence suggests that 
patients with symptomatic calf DVT benefit from treatment similar to that for proximal DVT,” 
but does not recommend specific durations of anticoagulation for calf DVT.8 If a patient with 
calf DVT has contraindications to anticoagulation, they state that: "serial ultrasound (e.g., at 3 
and 7 days) may be useful to evaluate for propagation of thromboses,” which typically occurs in 
the first week or two after diagnosis.8 
Clinical Commentary 
Without long-term anticoagulation (six to 12 weeks), patients with uncomplicated calf DVT have 
a 20 percent risk of clot propagation into proximal DVT,8 a 30 percent risk of recurrence,1,8 and 
a 20 percent or greater risk of developing post-thrombotic syndrome.1,7 Oral anticoagulation for 
DVT carries a steady 2 percent annual risk of major hemorrhage plus risk of minor hemorrhage.1 
It is appropriate to consider longer durations of anticoagulation for recurrent DVT, 
prothrombotic genotype or permanent risk factors, cancer, and idiopathic calf DVT. For these 
patients, clinicians must extrapolate from the AHRQ, ICSI, and ACCP recommendations for risk 
stratification and treatment duration, which are based on proximal DVT studies. 
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